A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion
Clinical trial NCT03347422 · COMPLETED
Trial details
- NCT number
- NCT03347422
- Sponsor
- Bioverativ, a Sanofi company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-17
- Primary completion
- 2021-12-03
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.